Acorda Therapeutics Debuts Art Exhibition Inspired by People with Parkinson’s at the 5th World Parkinson Congress
June 03 2019 - 7:00AM
Business Wire
- Framing OFF Through Art℠ gallery
illustrates individuals’ experience with OFF periods
- New research on OFF periods to be
presented at conference plenary session
Acorda Therapeutics, Inc. (NASDAQ: ACOR) today announced that it
will debut an art gallery inspired by people with Parkinson’s (PwP)
at the 5th World Parkinson Congress (WPC) in Kyoto, Japan. The six
pieces of art, ranging from acrylic sculptures to oil paintings,
are the centerpiece of Acorda’s Framing OFF Through Art initiative.
OFF periods are the re-emergence of Parkinson’s symptoms, and
affect approximately 40 percent of the one million people living
with Parkinson’s in the U.S. This initiative builds on Acorda’s
“Live Well. Do Tell.℠” program; its goal is to help initiate
effective conversations about OFF periods between PwPs and their
healthcare professionals.
Framing OFF Through Art uses the power of art to help PwPs
better identify and articulate their experiences with OFF periods.
It includes a series of artworks inspired by the personal
stories of people with Parkinson’s and their care partners. The
artworks were created by artists who also have a personal
connection to the disease. Conference attendees can view the
gallery and learn more at Acorda’s booth, #209.
“Research has consistently shown that OFF periods are among the
most common issues for people living with Parkinson’s disease,”
said Ron Cohen, M.D., Acorda’s President and CEO. “This
re-emergence of Parkinson’s symptoms can occur unexpectedly, up to
several times a day, despite daily medication regimens; this causes
enormous disruption and distress to the people who experience this.
In addition, each person’s experience with OFF periods is unique
and can be difficult to describe. We believe that people with
Parkinson’s will be able to see aspects of their own experiences
with Parkinson’s and OFF periods in these works of art, and use
this as an opportunity to discuss their symptoms with their
healthcare team.”
In addition, new research on the nature and diversity of
Parkinson’s disease will be presented by Connie Marras, M.D.,
Ph.D., associate professor at University Health Network, University
of Toronto, during the Morning Plenary on June 6, 2019, at 9:30 am
JST. Dr. Marras will also be presenting research around OFF periods
during the poster tour on June 5, 2019. The research on OFF periods
was supported by an Acorda Therapeutics research grant,
administered by The Michael J. Fox Foundation for Parkinson's
Research.
Acorda is also a gold sponsor of the WPC 2019 Art Walk – a
series of art, live music and dance exhibits. One of these
exhibits, “Soaring with Hope for PD,” features an installation of
15,000 origami cranes with messages of hope from 39 countries.
About “Live Well. Do Tell.”
“Live Well. Do Tell.” is an initiative created by Acorda with
input from a multi-disciplinary Steering Committee of Parkinson’s
community leaders. The goal of the program is to develop tools to
address communication gaps among people with Parkinson’s, their
care partners and their healthcare professionals.
The Steering Committee included people with Parkinson’s, care
partners, movement disorder specialists, a nurse practitioner and
representatives from key advocacy groups, including the American
Parkinson’s Disease Association, Caregiver Action Network, Davis
Phinney Foundation, The Michael J. Fox Foundation, Parkinson’s
Foundation, the Parkinson & Movement Disorder Alliance and the
World Parkinson Coalition.
For more information about “Live Well. Do Tell.” and Framing OFF
Through Art, visit LiveWellDoTell.org.
About Parkinson’s and OFF Periods
Parkinson’s is a progressive neurodegenerative disorder
resulting from the gradual loss of certain neurons. These neurons
are responsible for producing dopamine and that loss causes a range
of symptoms including impaired movement, muscle stiffness and
tremors. As Parkinson’s progresses, people are likely to experience
OFF periods, which are characterized by the return of Parkinson’s
motor and non-motor symptoms; these can occur even in the presence
of regular maintenance therapy. Approximately one million people in
the U.S. and 10 million people worldwide are living with
Parkinson’s; approximately 40 percent of people with Parkinson’s in
the U.S. are estimated to experience OFF periods.
About Acorda Therapeutics
Acorda Therapeutics develops therapies to restore function and
improve the lives of people with neurological disorders. For more
information on Acorda products and pipeline, visit:
https://www.acorda.com/products.
Forward-Looking Statement
This press release includes forward-looking statements. All
statements, other than statements of historical facts, regarding
management's expectations, beliefs, goals, plans or prospects
should be considered forward-looking. These statements are subject
to risks and uncertainties that could cause actual results to
differ materially, including: we may not be able to successfully
market Inbrija or any other products under development; risks
associated with complex, regulated manufacturing processes for
pharmaceuticals, which could affect whether we have sufficient
commercial supply of Inbrija to meet market demand; third party
payers (including governmental agencies) may not reimburse for the
use of Inbrija or our other products at acceptable rates or at all
and may impose restrictive prior authorization requirements that
limit or block prescriptions; competition for Inbrija, Ampyra and
other products we may develop and market in the future, including
increasing competition and accompanying loss of revenues in the
U.S. from generic versions of Ampyra (dalfampridine) following our
loss of patent exclusivity; the ability to realize the benefits
anticipated from acquisitions, among other reasons because acquired
development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the
risks specifically relevant to acquired programs generally improves
over time; we may need to raise additional funds to finance our
operations and may not be able to do so on acceptable terms; the
risk of unfavorable results from future studies of Inbrija
(levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed
programs; the occurrence of adverse safety events with our
products; the outcome (by judgment or settlement) and costs of
legal, administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class action litigation; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190603005010/en/
MEDIA:Tierney Saccavino(914)
326-5104tsaccavino@acorda.com
INVESTOR RELATIONS:Felicia Vonella(914)
326-5146fvonella@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Apr 2023 to Apr 2024